Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardiol Therapeutics ( (TSE:CRDL) ) has provided an announcement.
Cardiol Therapeutics Inc. announced its upcoming Annual General Meeting for securityholders, scheduled for May 28, 2025. The record date for notice and voting is set for April 10, 2025. This meeting is crucial for stakeholders as it provides an opportunity to discuss the company’s strategic direction and operational updates, potentially impacting its market positioning and future growth.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company is primarily engaged in creating innovative therapies for patients with inflammatory heart disease, aiming to address significant unmet medical needs in this market.
YTD Price Performance: -16.06%
Average Trading Volume: 293,091
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $91.58M
For detailed information about CRDL stock, go to TipRanks’ Stock Analysis page.